Menu
Search
|

Menu

Close
X

Cleveland Biolabs Inc CBLI.OQ (NASDAQ Stock Exchange Capital Market)

3.43 USD
-0.01 (-0.29%)
As of Feb 17
chart
Previous Close 3.44
Open 3.45
Volume 1,708
3m Avg Volume 6,420
Today’s High 3.45
Today’s Low 3.35
52 Week High 5.55
52 Week Low 1.41
Shares Outstanding (mil) 11.28
Market Capitalization (mil) 39.37
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
4
FY15
3
EPS (USD)
FY17
-0.764
FY16
-0.242
FY15
-2.694
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
13.52
5.77
Price to Book (MRQ)
vs sector
8.54
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-119.26
14.43
Return on Equity (TTM)
vs sector
-119.07
16.13

EXECUTIVE LEADERSHIP

Langdon Miller
President, Since 2015
Salary: $193,575.00
Bonus: --
Yakov Kogan
Chief Executive Officer, Principal Financial Officer, Since 2017
Salary: $276,866.00
Bonus: --
Andrei Gudkov
Chief Scientific Officer, Since 2003
Salary: $119,257.00
Bonus: --
Alexander Andryushechkin
Independent Director, Since 2016
Salary: --
Bonus: --
Anna Evdokimova
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

73 High St
BUFFALO   NY   14203-1149

Phone: +1716.8496810

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

SPONSORED STORIES